Join our Community
Support ToI and remove all ads
Learn more
×

Mylan

The Horsham, Pennsylvania, offices of Teva Pharmaceuticals (AP Photo/George Widman)
From the WebAugust 14, 2019, 6:50 pm
US lawmakers push Mylan, Teva over drug pricing probe
Reuters: The head of the US House of Representative’s oversight panel has asked three drugmakers to hand in documents, accusing them of ‘efforts to stonewall’ probe
Copaxone, the only non-interferon multiple sclerosis treatment, was developed by Teva Pharmaceuticals in the mid-1990s. (Weizmann Institute of Science/JTA)
From the WebJuly 11, 2018, 6:20 pm
Mylan cuts price of generic Copaxone offering by 60%
Calcalist: Bernstein analyst Ronny Gal says Teva’s competitor has cut the wholesale acquisition cost of the generic version of the Multiple Sclerosis drug from $5,000 to $1,900
Illustrative image of the Tel Aviv Stock Exchange, on March 14, 2017. (Roy Alima/Flash90)
From the WebNovember 12, 2017, 11:11 am
Mylan to delist from TASE
Globes: The decision by the US generics drug company is a blow to the Tel Aviv Stock Exchange’s hopes for a recovery in volumes, interest
Copaxone, the only non-interferon multiple sclerosis treatment, was developed by Teva Pharmaceuticals in the mid-1990s. (Weizmann Institute of Science/JTA)
October 26, 2017, 6:00 pm
In blow to Teva, UK court rules in favor of Copaxone patent challenge
Pharma giant Mylan says a UK court has ruled in favor of its challenge to the patent of Teva’s flagship drug for multiple sclerosis
By Shoshanna Solomon
The Israeli drug company TEVA Pharmaceutical Industries, in Jerusalem, on August 6, 2017. (Yonatan Sindel/Flash90)
October 8, 2017, 11:26 am
Teva shares plunge as competitors get nod for copycat flagship drug
Tel Aviv drop follows declines in New York last week on the news Mylan will start marketing generic version of Copaxone for multiple sclerosis
By Shoshanna Solomon
A broker at the Tel Aviv Stock Exchange (photo credit: Moshe Shai/Flash90)
From the WebNovember 5, 2015, 12:41 am
Mylan lists in Tel Aviv in latest salvo in Perrigo battle
Bloomberg: An ongoing business battle took on an Israeli twist as two drug giants based abroad choose the TASE for their showdown
From the WebMay 1, 2015, 4:52 am
Teva lifts 2015 earnings forecast as pursues Mylan bid
Reuters: Investors are pleased with the Israeli drug firm’s efforts to expand, even if they have been rebuffed for now
The Jerusalem office of the Israeli drug company Teva Pharmaceuticals (Yonatan Sindel/Flash90)
April 27, 2015, 7:47 pm
Mylan rebuffs Teva again; calls bid low, insincere
Generic drug company rejects $40.1-billion takeover offer from Israeli pharmaceutical power for second time
By AFP
Load More
Sign in or Join The Times of Israel Community
Paying ToI Community members are invited to comment on articles
Please use the following structure: example@domain.com
Or Continue with
By joining you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Join The Times of Israel Community
Only ToI Community members can comment below articles
Forgot your password? / Send me a login link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.
Back to top
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.